Kirin Acquires Jamieson Wellness for C$2.5bn, Bolstering North American Presence
Kirin Holdings' C$2.5 billion acquisition of Jamieson Wellness signals aggressive expansion into North America, creating new competitive pressures and opportunities for market consolidation.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Tokyo, Japan — 06 August 2026
Kirin Holdings Company has agreed to acquire Canadian supplement brand Jamieson Wellness Inc. for C$2.5 billion, integrating it as a wholly-owned subsidiary. This strategic move directly advances Kirin's Health Science business expansion into the North American market, complementing its existing acquisitions of Blackmores in Australia and FANCL in Japan. The transaction, reported by NutraIngredients Global, solidifies Kirin's regional footprint across Asia, Oceania, and now North America, positioning Jamieson's established brand equity and market presence as crucial assets.
The acquisition represents a significant consolidation within the global supplement industry, indicating a trend towards larger, multi-market players. Kirin's focus on its Health Science division underscores a long-term commitment to the consumer health sector. This expansion will likely lead to intensified competition for shelf space, ingredient sourcing, and consumer attention in the Canadian and broader North American supplement markets. Manufacturers and brand owners should assess their current market positioning and distribution strategies in anticipation of a more formidable competitor with substantial financial backing.
The deal remains subject to standard shareholder and regulatory approvals, with a projected closing in the fourth quarter of 2026. This timeline provides a window for competitors to analyse the potential impacts and adapt their business models. Procurement teams may see shifts in ingredient demand and pricing, particularly for common supplement formulations, as Kirin integrates Jamieson into its larger supply chain. Regulatory teams should monitor any changes in product development or claims strategy post-acquisition, as large players often set new benchmarks for compliance.
What this means for Canada
Canadian brand owners face increased competition, particularly in established retail channels where Jamieson has strong penetration. The C$2.5 billion investment signals Kirin's intent to dominate, potentially compressing margins for local manufacturers reliant on similar product categories. Regulatory teams should anticipate enhanced scrutiny of product claims and efficacy, aligning with a global player's compliance standards. Opportunities may arise for contract manufacturers to service the expanded entity or for niche brands to differentiate themselves through innovation. Expect potential shifts in private label offerings as Kirin optimises Jamieson's production capabilities and market reach.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.